A vs IDXX
Agilent Technologies and Idexx Laboratories, both Healthcare
Idexx Laboratories is the larger company at $44B against $36B. On trailing earnings A is the cheaper of the two at a P/E of 33.6 against 36.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year A returned +34% against -21% for IDXX.
| Figure | A | IDXX |
|---|---|---|
| Last close | $170 | $518 |
| Market cap | $36B | $44B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 33.6 | 36.4 |
| Dividend yield | 0.6% | n/a |
| 1-year return | +34% | -21% |
| 5-year return | +2.4% | -21% |
| RyuScoresector-relative, 1–10 | 70/100 | 70/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Agilent Technologies
Revenue of $1.9B in Q3 2026, net income $362M. Its largest reported line is Life Sciences And Diagnostics Markets, 48% of the disclosed total.
Idexx Laboratories
Revenue of $1.2B in Q2 2026, net income $338M. Its largest reported line is Vet Lab Consumables, 35% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.